Compare Stocks

Date Range: 

 NTN BuzztimeBenitec BiopharmaMateon TherapeuticsQ BioMedArtelo Biosciences
SymbolNYSEAMERICAN:NTNNASDAQ:BNTCOTCMKTS:MATNOTCMKTS:QBIONASDAQ:ARTL
Price Information
Current Price$32.30$4.35$0.32$1.03$1.23
52 Week RangeN/AHoldBuyN/ABuy
MarketRank™
Overall Score0.40.61.50.51.6
Analysis Score0.00.03.50.03.5
Community Score2.02.32.62.62.7
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.80.01.7
Earnings & Valuation Score0.00.60.60.00.0
Analyst Ratings
Consensus RecommendationN/AHoldBuyN/ABuy
Consensus Price TargetN/AN/A$3.00N/A$7.00
% Upside from Price TargetN/AN/A852.38% upsideN/A469.11% upside
Trade Information
Market Cap$96.16 million$20.96 million$28.43 million$26.78 million$28.45 million
Beta0.721.841.522.12.52
Average Volume1,629,8162,053,399338,444105,8216,794,023
Sales & Book Value
Annual Revenue$19.81 million$100,000.00N/AN/AN/A
Price / Sales4.85209.58N/AN/AN/A
Cashflow$7.37 per share$4.39 per shareN/AN/AN/A
Price / Cash4.380.99N/AN/AN/A
Book Value$1.76 per share$19.75 per share$0.20 per share($0.26) per share$0.78 per share
Price / Book18.350.22N/AN/AN/A
Profitability
Net Income$-2,050,000.00$-8,270,000.00$-6,640,000.00$-10,280,000.00$-4,660,000.00
EPSN/A($8.10)N/AN/AN/A
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-61.42%N/AN/AN/AN/A
Return on Equity (ROE)-162.54%N/A-64.66%N/A-96.32%
Return on Assets (ROA)-49.94%N/A-42.92%-678.41%-88.73%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.30%N/AN/AN/AN/A
Current Ratio0.95%N/A0.17%0.88%15.43%
Quick Ratio0.95%N/A0.17%0.88%15.43%
Ownership Information
Institutional Ownership Percentage6.31%5.72%0.04%0.04%N/A
Insider Ownership Percentage24.20%1.00%39.22%N/A3.36%
Miscellaneous
Employees19141343
Shares Outstanding2.98 million4.82 million90.24 million26.12 million23.13 million
Next Earnings Date5/18/2021 (Estimated)N/AN/A7/21/2021 (Estimated)7/12/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021
finance.yahoo.com - May 6 at 8:30 AM
Kintara Therapeutics Appoints Tamara A. Seymour to Board of DirectorsKintara Therapeutics Appoints Tamara A. Seymour to Board of Directors
finance.yahoo.com - May 4 at 8:33 AM
Artelo Biosciences, Inc. (NASDAQ:ARTL) Jumps 1.18%: A Look At The most Likely Path Going ForwardArtelo Biosciences, Inc. (NASDAQ:ARTL) Jumps 1.18%: A Look At The most Likely Path Going Forward
stocksregister.com - April 24 at 5:42 PM
Financial Comparison: Enochian Biosciences (NASDAQ:ENOB) vs. Artelo Biosciences (NASDAQ:ARTL)Financial Comparison: Enochian Biosciences (NASDAQ:ENOB) vs. Artelo Biosciences (NASDAQ:ARTL)
americanbankingnews.com - April 21 at 10:14 PM
Artelo Biosciences Inc. [ARTL] gain 72.60% so far this year. What now?Artelo Biosciences Inc. [ARTL] gain 72.60% so far this year. What now?
dbtnews.com - April 20 at 3:46 PM
Were Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash WiselyWe're Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash Wisely
finance.yahoo.com - April 20 at 10:46 AM
Analysts think Artelo Biosciences, Inc. (NASDAQ:ARTL) could rise 503.45% from current levelsAnalysts think Artelo Biosciences, Inc. (NASDAQ:ARTL) could rise 503.45% from current levels
stocksregister.com - April 19 at 12:39 PM
Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update | MorningstarArtelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update | Morningstar
morningstar.com - April 15 at 6:06 PM
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss | MorningstarArtelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss | Morningstar
morningstar.com - April 14 at 5:43 AM
Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business UpdateArtelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
finance.yahoo.com - April 13 at 9:29 AM
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of ...Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of ...
apnews.com - April 12 at 1:16 PM
Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossArtelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
finance.yahoo.com - April 12 at 1:16 PM
Will Artelo Biosciences (NASDAQ:ARTL) Spend Its Cash Wisely?Will Artelo Biosciences (NASDAQ:ARTL) Spend Its Cash Wisely?
nasdaq.com - April 8 at 8:22 AM
Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)
seekingalpha.com - March 25 at 10:34 AM
Artelo Biosciences Inc. (NASDAQ: ARTL) Featured in Virtual Coverage of Investor Summit Groups Q1 Virtual SummitArtelo Biosciences Inc. (NASDAQ: ARTL) Featured in Virtual Coverage of Investor Summit Group's Q1 Virtual Summit
marketwatch.com - March 23 at 8:59 AM
Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 ...Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 ...
apnews.com - March 20 at 8:20 AM
Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker DevelopmentArtelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
finance.yahoo.com - March 19 at 2:28 PM
Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker DevelopmentArtelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
finance.yahoo.com - March 19 at 2:28 PM
Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rdArtelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
markets.businessinsider.com - March 11 at 9:25 AM
Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rdArtelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
finance.yahoo.com - March 11 at 9:25 AM
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to ...Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to ...
apnews.com - March 10 at 8:57 AM
ARTL Stock Price Increases Over 30% Pre-Market: Why It HappenedARTL Stock Price Increases Over 30% Pre-Market: Why It Happened
pulse2.com - March 10 at 8:57 AM
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of DirectorsArtelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
finance.yahoo.com - March 9 at 8:57 AM
Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9thArtelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
finance.yahoo.com - March 2 at 8:49 AM
What To Know About Artelo Bio And Trinity Colleges Partnership For Cannabinoid And Cancer ResearchWhat To Know About Artelo Bio And Trinity College's Partnership For Cannabinoid And Cancer Research
benzinga.com - February 19 at 5:39 PM
DateCompanyBrokerageAction
10/5/2020Benitec BiopharmaLADENBURG THALM/SH SHDowngrade
12/7/2020Mateon TherapeuticsLitchfield Hills ResearchInitiated Coverage
4/22/2019Mateon TherapeuticsHC WainwrightReiterated Rating
5/10/2019Q BioMedBrookline Capital ManagementReiterated Rating
11/29/2018Q BioMedRoth CapitalDowngrade
1/7/2021Artelo BiosciencesMaxim GroupUpgrade
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.